Bleeding is the most concerning complication associated with anticoagulant therapy but poorly characterized and important for risk

 

Abstract

Bleeding is the most concerning complication associated with anticoagulant therapy but poorly characterized and important for risk/benefit assessment. We developed a risk stratification score to predict vitamin K antagonist (VKA)-associated bleeding in venous thromboembolism (VTE) using the UK Clinical Practice Research Datalink. Significant bleeding events in outpatients consisted of major bleeding and clinically relevant non-major bleeding requiring hospitalisation (CRNMB-H) within 90 days of VKA initiation. A scoring scheme for predicting bleeding was developed from subhazard ratios, validated using cross-validation and expressed by the C-statistic. The study cohort consisted of 10,010 patients with first VTE receiving initial VKA treatment, mean age 62·2 years. Between 2008 and 2016, 167 significant bleeding events were recorded (1·7%), i.e. incidence rate was 7·4/100 person-years. Independent predictors for community-acquired significant bleeding included active cancer, trauma/surgical procedure, male gender, dementia, liver disease, anaemia, history of bleeding, cerebrovascular, renal and chronic pulmonary disease, VTE presenting as pulmonary embolism and age over 75. The overall C-statistic was 0·68 (95% CI, 0·60-0·76), 0·75 (0·60-0·88) for major bleeding and 0·65 (0·55-0·75) for CRNMB-H, and higher than in other risk schemes applied to our study population. The developed risk score may identify patients having a significant bleeding risk, in particular major bleeding events, in outpatients.

PMID: 31997309 [PubMed - as supplied by publisher]

14:38

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

14:38

In reply to this message

pubmed: ctoall&ca or conall

Preventive Cardio-Oncology: The Time Has Come.

Related Articles

Preventive Cardio-Oncology: The Time Has Come.

Front Cardiovasc Med. 2019;6:187

Authors: Brown SA

PMID: 31998754 [PubMed]

1 February 2020

12:34

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

12:34

In reply to this message

pubmed: ctoall&ca or conall

Cardiac PET/CT-Determined Amyloid Light Chain Depositions: A New Risk Biomarker?

Related Articles

Cardiac PET/CT-Determined Amyloid Light Chain Depositions: A New Risk Biomarker?

J Am Coll Cardiol. 2020 Feb 04;75(4):391-394

Authors: Schindler TH, Gropler RJ, Lenihan DJ

PMID: 32000950 [PubMed - in process]

12:34

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

12:34

In reply to this message

pubmed: ctoall&ca or conall

A case report on the effect of rituximab on pyothorax-associated lymphoma.

//www.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--tools.ovid.com-images-wklogo.jpg //www.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--www.ncbi.nlm.nih.gov-corehtml-pmc-pmcgifs-pubmed-pmc.png Related Articles

A case report on the effect of rituximab on pyothorax-associated lymphoma.

Medicine (Baltimore). 2019 Dec;98(50):e18393

Authors: Wang F, Lan H